The Conversation (0)
Stellar Biotechnologies Inc. (OTCQB:SBOTF, TSXV:KLH) announced that it has submitted a Biologics Master File to the United States Food and Drug Administration Center for Biologics Evaluation and Research for the company’s subunit Keyhole Limpet Hemocyanin (KLH).
Stellar Biotechnologies Inc. (OTCQB:SBOTF, TSXV:KLH) announced that it has submitted a Biologics Master File to the United States Food and Drug Administration Center for Biologics Evaluation and Research for the company’s subunit Keyhole Limpet Hemocyanin (KLH).
As quoted in the press release:
This new BB-MF is intended to support Stellar’s KLH customers who file applications under the CBER division, thus expanding applicability of the Company’s KLH for broader uses.
Click here to read the full Stellar Biotechnologies Inc. (OTCQB:SBOTF, TSXV:KLH) press release.
